Prestige Consumer Healthcare Inc. (PBH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Prestige Consumer Healthcare Inc. (PBH) Healthcare & Pipeline Overview

Prestige Consumer Healthcare Inc. focuses on the development, manufacturing, and distribution of over-the-counter healthcare products in North America and internationally. With a diverse brand portfolio and a wide distribution network, the company maintains a strong presence in the consumer healthcare market, characterized by stable demand and brand loyalty.

What Is the Investment Thesis for PBH?

Prestige Consumer Healthcare Inc. presents a compelling investment case due to its established position in the stable OTC healthcare market. The company's diverse brand portfolio, coupled with its extensive distribution network, provides a solid foundation for consistent revenue generation. With a P/E ratio of 15.5 and a profit margin of 16.9%, the company demonstrates financial stability. Growth catalysts include strategic acquisitions of complementary brands and expansion into new geographic markets. However, investors may want to evaluate potential risks such as competition from larger pharmaceutical companies and the impact of changing consumer preferences. The company's beta of 0.47 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

PBH Key Highlights

Market capitalization of $2.39B, reflecting substantial investor confidence in the company's market position.

• P/E ratio of 15.5, indicating a potentially undervalued stock compared to industry peers.
• Profit margin of 16.9%, showcasing efficient cost management and strong pricing power.
• Gross margin of 56.4%, highlighting the company's ability to maintain profitability across its product lines.
• Beta of 0.47, suggesting lower volatility compared to the overall market, making it a potentially stable investment.

Who Are PBH's Competitors?

PBH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PBH's Key Strengths?

Strong brand portfolio with established consumer recognition.

• Extensive distribution network across multiple channels.
• Proven track record of acquiring and revitalizing brands.
• Stable revenue generation due to the essential nature of OTC products.

What Are PBH's Weaknesses?

Reliance on acquisitions for growth, which can be unpredictable.

• Limited presence in emerging markets compared to larger competitors.
• Vulnerability to changing consumer preferences and trends.
• Potential for product liability claims and recalls.

What Could Drive PBH Stock Higher?

Potential acquisitions of complementary OTC brands to expand product portfolio.

• Continued focus on digital marketing and e-commerce initiatives to drive online sales.
• Expansion into new international markets to increase revenue streams.

What Are the Key Risks for PBH?

Financial-distress signal — its Altman Z-Score of 1.63 sits in the distress zone (elevated bankruptcy risk).

• Intense competition from larger pharmaceutical companies and generic brands.
• Regulatory changes and increased scrutiny of OTC products.
• Economic downturns that could reduce consumer spending on non-essential healthcare products.
• Supply chain disruptions and rising raw material costs.

What Are the Growth Opportunities for PBH?

• Strategic Acquisitions: Prestige Consumer Healthcare can drive growth through the acquisition of complementary OTC brands. The fragmented nature of the OTC market provides opportunities to acquire smaller, established brands with strong regional presence or niche product offerings. Successfully integrating these brands into Prestige's existing distribution network can lead to significant revenue synergies. The timeline for realizing benefits from acquisitions is typically 1-3 years, with market size potential dependent on the acquired brand's revenue, which could range from $50 million to $200 million per acquisition.
• International Expansion: Expanding into new international markets represents a significant growth opportunity. Emerging markets, with their growing middle class and increasing healthcare awareness, offer substantial potential for OTC product sales. Prestige can leverage its existing brand portfolio and adapt its marketing strategies to suit local preferences. The timeline for successful international expansion is typically 3-5 years, with market size potential varying by region, potentially adding $100 million to $300 million in annual revenue.
• E-commerce Channel Development: Enhancing its e-commerce presence is crucial for reaching a broader customer base and capitalizing on the growing trend of online shopping. Investing in digital marketing, improving website functionality, and partnering with major e-commerce platforms can drive online sales. The timeline for significant e-commerce growth is 1-2 years, with the potential to increase online sales by 20-30% annually, contributing an additional $50 million to $100 million in revenue.
• Product Innovation: Introducing new and innovative OTC products can attract new customers and drive revenue growth. Focusing on developing products that address unmet consumer needs, such as natural or organic formulations, can differentiate Prestige from its competitors. The timeline for successful product innovation is typically 2-3 years, with the potential to generate $30 million to $70 million in annual revenue per successful product launch.
• Brand Revitalization: Prestige has a proven track record of acquiring and revitalizing established OTC brands. Continuing to focus on identifying underperforming brands with strong brand recognition and potential for growth can drive revenue. By investing in marketing, product reformulation, and distribution improvements, Prestige can unlock the hidden value of these brands. The timeline for brand revitalization is typically 1-3 years, with the potential to increase revenue by 10-20% per revitalized brand, contributing an additional $20 million to $50 million in revenue.

What Are PBH's Competitive Advantages?

• Established Brand Portfolio: Prestige owns a diverse portfolio of well-known and trusted OTC brands, creating customer loyalty and repeat purchases.
• Extensive Distribution Network: The company's wide distribution network provides access to a broad customer base, making it difficult for new entrants to compete.
• Acquisition Expertise: Prestige has a proven track record of acquiring and revitalizing established brands, creating a competitive advantage in the market.
• Regulatory Expertise: Navigating regulatory requirements for OTC products creates a barrier to entry for new competitors.

What Does PBH Do?

Prestige Consumer Healthcare Inc., founded in 1996 and headquartered in Tarrytown, New York, specializes in over-the-counter (OTC) health and personal care products. The company operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its product portfolio includes well-known brands such as BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. Additionally, Prestige offers Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. These products are distributed through mass merchandisers, drug stores, food stores, dollar stores, convenience stores, club stores, and e-commerce channels. Formerly known as Prestige Brands Holdings, Inc., the company rebranded to Prestige Consumer Healthcare Inc. in August 2018, reflecting its strategic focus on consumer healthcare. The company's success is rooted in its ability to acquire and revitalize established brands, leveraging its distribution network and marketing expertise to drive growth.

What Products and Services Does PBH Offer?

• Develops over-the-counter (OTC) health and personal care products.
• Manufactures a wide range of OTC products.
• Markets its products through various channels.
• Distributes products in the United States and internationally.
• Sells products through mass merchandisers, drug stores, and e-commerce platforms.
• Offers products in two segments: North American OTC Healthcare and International OTC Healthcare.

How Does PBH Make Money?

• Acquires and revitalizes established OTC brands.
• Leverages its distribution network to reach a broad customer base.
• Focuses on marketing and brand building to drive sales.
• Generates revenue through the sale of OTC products.

What Industry Does PBH Operate In?

Prestige Consumer Healthcare Inc. operates within the competitive over-the-counter (OTC) healthcare market. This market is characterized by stable demand, driven by consumers' ongoing needs for self-medication and preventative healthcare. The industry is influenced by factors such as regulatory changes, consumer preferences for natural and organic products, and the increasing prevalence of e-commerce. Prestige competes with larger pharmaceutical companies and other OTC product manufacturers. The company's focus on acquiring and revitalizing established brands differentiates it within the market.

Who Are PBH's Key Customers?

• Consumers seeking over-the-counter health and personal care products.
• Mass merchandisers such as Walmart and Target.
• Drug stores such as CVS and Walgreens.
• E-commerce platforms such as Amazon.

Company Profile

Prestige Consumer Healthcare Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Tarrytown, US. The company is led by CEO Ronald Lombardi. PBH has traded publicly since 2005.

Return on equity for Prestige Consumer Healthcare Inc. stands at 10.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.4%, showing how much profit it generates from its asset base. PBH trades at a trailing price-to-earnings ratio of 15.50, below the Healthcare sector average of ~23x. Its free cash flow yield is 11.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.3%, the inverse of the P/E and a quick read on earnings relative to price.

PBH Valuation & Market Position

With a $2.39B market cap, Prestige Consumer Healthcare Inc. sits in the mid-cap segment of the market. Relative to its peer group, PBH's quantitative score of 64/100 is roughly in line with the peer average of 67/100.

Quarterly Financial Performance: Prestige Consumer Healthcare Inc.

Revenue for Prestige Consumer Healthcare Inc. came in at $265.7M during Q2 2026, a 5.6% contraction versus the preceding quarter. The company recorded net income of $29.2M, with diluted EPS of $0.61. Revenue has contracted over three consecutive quarters, which investors in this mid-cap Healthcare stock should monitor closely. Across the four most recent quarters, PBH averaged $0.89 in diluted EPS.

Prestige Consumer Healthcare Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.63 places it in the distress zone, a signal of elevated financial risk.

Prestige Consumer Healthcare Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.0% above estimates on average.

Wall Street analysts project Prestige Consumer Healthcare Inc. revenue of about $1.10B for fiscal 2026, with EPS near $4.54. The estimate reflects 6 contributing analysts.

PBH Financials

PBH Latest News

PBH Analyst Consensus

PBH MoonshotScore

PBH Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources